Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation

Jennifer H. Cao, Matthew Mulvahill, Li Zhang, Brian C. Joondeph, Mark S. Dacey

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Purpose: To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis.

Design: Retrospective chart review.

Participants: A total of 27 consecutive patients with persistent macular edema resistant to standard shortterm therapy despite quiescent noninfectious intermediate or posterior uveitis.

Methods: Each patient was treated with a DEX 0.7 mg implant.

Main Outcome Measures: Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection.

Results: A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation.

Conclusions: The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events.

Original languageEnglish (US)
Pages (from-to)1871-1876
Number of pages6
JournalOphthalmology
Volume121
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Macular Edema
Dexamethasone
Inflammation
Visual Acuity
Therapeutics
Intermediate Uveitis
Posterior Uveitis
Outcome Assessment (Health Care)
Injections
Uveitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. / Cao, Jennifer H.; Mulvahill, Matthew; Zhang, Li; Joondeph, Brian C.; Dacey, Mark S.

In: Ophthalmology, Vol. 121, No. 10, 01.01.2014, p. 1871-1876.

Research output: Contribution to journalArticle

Cao, Jennifer H. ; Mulvahill, Matthew ; Zhang, Li ; Joondeph, Brian C. ; Dacey, Mark S. / Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. In: Ophthalmology. 2014 ; Vol. 121, No. 10. pp. 1871-1876.
@article{4af726a008094fd4bd06b556109b597f,
title = "Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation",
abstract = "Purpose: To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis.Design: Retrospective chart review.Participants: A total of 27 consecutive patients with persistent macular edema resistant to standard shortterm therapy despite quiescent noninfectious intermediate or posterior uveitis.Methods: Each patient was treated with a DEX 0.7 mg implant.Main Outcome Measures: Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection.Results: A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation.Conclusions: The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events.",
author = "Cao, {Jennifer H.} and Matthew Mulvahill and Li Zhang and Joondeph, {Brian C.} and Dacey, {Mark S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ophtha.2014.04.012",
language = "English (US)",
volume = "121",
pages = "1871--1876",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation

AU - Cao, Jennifer H.

AU - Mulvahill, Matthew

AU - Zhang, Li

AU - Joondeph, Brian C.

AU - Dacey, Mark S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis.Design: Retrospective chart review.Participants: A total of 27 consecutive patients with persistent macular edema resistant to standard shortterm therapy despite quiescent noninfectious intermediate or posterior uveitis.Methods: Each patient was treated with a DEX 0.7 mg implant.Main Outcome Measures: Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection.Results: A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation.Conclusions: The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events.

AB - Purpose: To examine the observational effectiveness of the dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc., Irvine, CA) in the treatment of noninfectious uveitic macular edema in patients with otherwise quiescent uveitis.Design: Retrospective chart review.Participants: A total of 27 consecutive patients with persistent macular edema resistant to standard shortterm therapy despite quiescent noninfectious intermediate or posterior uveitis.Methods: Each patient was treated with a DEX 0.7 mg implant.Main Outcome Measures: Primary outcome measure was resolution of macular edema 1 month after injection as measured by decrease in central macular thickness (CMT). Secondary outcome was change in visual acuity 1, 2, and 3 months after injection.Results: A total of 27 eyes of 27 patients were included for analysis. One eye was randomly selected for 6 of these patients who received bilateral DEX implants. There was a statistically significant reduction in mean CMT 1 month after DEX implantation (mean, 278.9 μm; range, 206-352 μm) compared with baseline (mean, 478.7 μm; range, 330-667 μm) (P < 0.0001). There was a statistically significant improvement in visual acuity at 3 months (logarithm of the minimum angle of resolution [logMAR] 0.41; 20/51) compared with baseline (logMAR 0.60; 20/80) (P = 0.0005). There were no major complications after DEX implantation.Conclusions: The DEX implant resulted in a statistically significant improvement in mean CMT and visual acuity without any serious adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84908136784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908136784&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2014.04.012

DO - 10.1016/j.ophtha.2014.04.012

M3 - Article

C2 - 24907061

AN - SCOPUS:84908136784

VL - 121

SP - 1871

EP - 1876

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 10

ER -